LEIDEN, Netherlands, Jan. 8, 2025 /PRNewswire/ -- Alesta Therapeutics, a biotechnology company focused on developing transformative small molecule therapies for rare diseases, today announced the ...

About Leap Therapeutics Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized ...

Edgewise Therapeutics (NASDAQ:EWTX) is building itself up as a good long-term biotech to hang onto. Especially, when you consider that it was able to report positive results from its phase 2 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Mirae Asset Global Investments Co. Ltd. grew its stake in Edgewise Therapeutics by 21.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,392 shares of the company’s stock ...

Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) traded down 2.5% during mid-day trading on Tuesday . The stock traded as low as $29.03 and last traded at $29.23.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tenaya Therapeutics’ clinical data readout for TN-201 showed promise in treating heart disease but the results were underwhelming and sent the stock tumbling. Insitro discovered a new ALS drug target.